Skip to main content

Dier Mardi's Form 4 filing

Madrigal Pharmaceuticals, Inc.MDGL · filed Mar 6, 2026

Accession no.
0001628280-26-015775
Filed
Mar 6, 2026
Trade date
Mar 4-6, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 13 non-derivative transactions and 1 derivative transaction. Open-market sales total $854.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dier MardiCIK 0001574591Officer (EVP and CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 4, 2026Common StockAGrant or awardAcquired+5,215$0.00$014,472Direct
Mar 6, 2026Common StockSSaleDisposed−646$431.94−$279,033.2413,826Direct
Mar 6, 2026Common StockSSaleDisposed−40$425.08−$17,003.213,786Direct
Mar 6, 2026Common StockSSaleDisposed−420$426.86F4−$179,281.213,366Direct
Mar 6, 2026Common StockSSaleDisposed−80$427.85F5−$34,22813,286Direct
Mar 6, 2026Common StockSSaleDisposed−160$429.00F6−$68,64013,126Direct
Mar 6, 2026Common StockSSaleDisposed−40$429.58−$17,183.213,086Direct
Mar 6, 2026Common StockSSaleDisposed−120$430.90F7−$51,70812,966Direct
Mar 6, 2026Common StockSSaleDisposed−116$432.56F8−$50,176.9612,850Direct
Mar 6, 2026Common StockSSaleDisposed−160$434.20F9−$69,47212,690Direct
Mar 6, 2026Common StockSSaleDisposed−80$435.32F10−$34,825.612,610Direct
Mar 6, 2026Common StockSSaleDisposed−80$436.69F11−$34,935.212,530Direct
Mar 6, 2026Common StockSSaleDisposed−40$437.65−$17,50612,490Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 4, 2026Common StockAGrant or awardAcquired+6,519$0.00$06,519Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive.

Referenced by the price of 1 transaction in Table I.

F11

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)